News
We send the latest information from SMC Laboratories.
Wnt/β-catenin in our NASH-HCC model: How does it correlate to human liver cancer?
The main cause of hepatocellular carcinogenesis today is chronic liver disease following HCV and HBV infection. By virtue of recent advances in treatment methods, the number of patients with HCC caused by these infections is expected to decrease in the future. On the other hand, the number of patients with NAFLD and NASH is…
CohBar, Inc. announces the completion of enrolment in the Phase 1b stage of the CB4211 clinical study of NASH and obesiy.
CohBar, Inc. (USA) announced on March 29, 2021, that the completion of enrolment in the Phase 1b stage of the CB4211 clinical study of NASH and obesity. For detail information, see the CohBar's press release. https://www.cohbar.com/news-media/press-releases/detail/143/cohbar-completes-enrollment-in-the-phase-1b-clinical-trial CB4211 is a first-in-class mitochondria based therapeutic. The peptide used the STAM™ mouse model for non-clinical studies,…
Positive control for UUO kidney fibrosis
We are excited to share with you an update about a newly established positive control – an ALK5 inhibitor – for our UUO-induced renal fibrosis model. This ALK5 inhibitor has an inhibitory effect on the TGF-beta/ALK5 signaling pathway, which plays a central role in renal fibrosis. Below is the result of fibrosis analysis from…
Gannex Announces Positive Clinical Results in Overweight and Obese Subjects for Its THR-b Agonist ASC41
Gannex (Shanghai, China) has announced positive clinical results in overweigth and obse subjects for its THR-b agonist ASC41. For detail information, see the Gannex's press release. https://www.ascletis.com/news_detail/175/id/462.html
TERNS announces FDA clearance of investigational new drug application for first-in-human phase 1 trial of TERN-501, its THR-beta agonist in development for the treatment of NASH
TERNS Pharmaceuticals, Inc. (USA) has announced FDA clearance of investigational new drug aplication for first-in-human phase 1 trial of TERN-501, its THR-beta agonist in development for the treatment of NASH. For detail information, see the TERNS's press release. https://ir.ternspharma.com/news-releases/news-release-details/terns-announces-fda-clearance-investigational-new-drug-ind
Inventiva announces design of Phase III clinical trial with Ianifibranor in NASH
Inventiva (France) has announced design of Phase III clinical trial with Ianifibranor in NASH For detail information, see the Inventiva's press release. https://www.globenewswire.com/news-release/2021/01/05/2153793/0/en/Inventiva-announces-design-of-Phase-III-clinical-trial-with-lanifibranor-in-NASH.html
Hepion pharma announces positive top line data for low dose CRV431 in Phase 2a "AMBITION' clinical trial for treatment of advanced NASH.
Hepion pharma (NJ), which is our client, has announced positive top line data for low dose CRV431 in Phase 2a “AMBITION” clincal trial for treatment of advanced NASH. CRV431 is a cyclophillin inhibitor. The compound has been used in nonclinical pharmacology study using the STAMTM mouse model and has been shown to improve liver…
Lipocine announces positive topline Phase 2 results from LPCN1144 ongoing Lift study in biopsy-confirmed NASH subjects
Lipocine (USA, UA) announced on 12 January, 2021, positive topline Phase 2 results from LPCN1144 ongoing LiFT study in biopsy-confirmed NASH subjects. For detailed information, see the below URL. https://www.lipocine.com/news-article/lipocine-announces-positive-topline-phase-2-results-from-lpcn-1144-ongoing-lift-study-in-biopsy-confirmed-nash-subjects/
Chemomab announces positive Phase Ib results of its SPARK study testing CM-101 in NAFLD patients
Chemomab Ltd.(Israel) announced on 5 January, 2021, positive Phase Ib results of its SPARK study testing CM-101 in NAFLD patients. For detailed information, see the below URL. https://www.chemomab.com/uploads/pr-chemomab-spark-results.pdf CM-101, a monoclonal antibody designed to bind and block CCL24 activity. The antibody used the STAM™ mouse model for non-clinical studies, and data showing the…
Can-Fite reports on progress with its Namodenoson NASH program
Can-Fite (Israel) reports on 14 December, 2020, on progress with its Namodenoson NASH program. For detailed information, see the below URL. https://www.cytodyn.com/newsroom/press-releases/detail/489/cytodyn-announces-first-patient-enrolled-in-phase-2-trial